Avastin

Mar 30, 2022

Patent protection and expiration is one of the hot topics in the healthcare industry. Patent protection results in high sales and profits for the initial developers and innovators of the drugs, and as per various estimates, the gross profit margins for the Patent protected drugs exceed 90% in some cases. However, t...

Dec 22, 2021

The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a compelling economic value proposition. This has been a considerable element in expanding the biosimilar market, and the future of this sector appears promising. Many pharmaceutical companies from across the globe are proactively...

Dec 15, 2021

Since the first biosimilar drug was approved in 2006, the EU has led the way in biosimilar regulation. Over the last decade, the EU has authorized the most biosimilars globally, gathering significant expertise with their usage and safety. Over ten years of clinical experience has shown that biosimilars licensed by ...

May 12, 2020

MyoKardia has announced the promising results of Phase III clinical trials of its lead drug mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Following the announcement, shares of the California-based company skyrocketed. The Phase III clinical trial - EXPLORER-HCM – demonstrated the pot...

May 03, 2019

Ovarian Cancer is a type of cancer that starts in Ovaries when the cells in the ovaries keep on dividing abnormally. It can affect either one or both the ovaries. Cancers that start in the ovaries can metastasize to other parts of the body. Ovarian cancer is not a single disease but can be defined as a cluster of d...

Oct 16, 2017

Wet AMD is a chronic eye disease that causes blurred vision or a blind spot in a person’s visual field. It is characterized by abnormal blood vessels that leak blood and fluids into the macula, a region of the eye that is responsible for sharp, central vision. Age-related macular degeneration (AMD) is a common eye c...

Jul 25, 2014

The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of t...